ACTH response to desmopressin in a patient with acromegaly; Expression of corticotropin-releasing factor, urocortins and vasopressin V1b receptor in GH-producing pituitary adenoma

Multiple aberrant hormone receptors in Cushing's syndrome

“…Immunohistochemistry revealed positive immunostaining for CRF, urocoritn1 (Ucn1), urocortin3 (Ucn3) and vasopressin V1b receptor in the adenoma. These observations raised the possibility that DDAVP caused an ACTH response, perhaps via the paracrine effects of tumor-derived CRF and Ucn1 (139).…”

Corticotropin Releasing Hormone Is Correlated With Tumorigenesis of Gastric Cancer

“…Published data indicate that the corticotropin releasing hormone (CRH) can be expressed in cancer cell lines (9) and cancer tissues (10). CRH is a 41-amino acid peptide derived from a 196-amino acid preprohormone.…”

Expression of Urocortin I in Normal Tissues and Malignant Tumors

“…In addition to normal and diseased tissues, numerous recent studies have revealed UCN I is expressed in various cancer cells and cell lines, including human glioblastoma cells (KSN42, T98G, RT2, 9L, A172, and U-138 MG cells) [62] , pituitary adenoma cells [44,63] , malignant melanoma cells [42] , both thyroid carcinoma and pheochromocytoma (multiple endocrine neoplasia type II) cells [64] , breast cancer cells [65] , gastric adenocarcinoma cells and the STKM-1 cell line [66,67] , primary and metastatic liver carcinoma cells [22] , pancreatic ductal adenocarcinoma cells and neoplasms [68] , the MIN6 insulinoma cell line [33] , clear cell renal cell carcinoma cells [51] , NCI-H295R human adrenal carcinoma cells [69] , human endometrial carcinoma cells [70] , and human prostate adenocarcinoma cells [59] . Interestingly, UCN I and its working receptors (CRFR1 and CRFR2) do not always co-localize; for example, they do not colocalize in RT2 and 9L human glioblastoma cells [62] .…”